Previous 10 | Next 10 |
Image source: The Motley Fool. Cue Biopharma, Inc. (NASDAQ: CUE) Q1 2020 Earnings Call May 19, 2020 , 4:30 p.m. ET Operator Continue reading
Cue Biopharma (NASDAQ: CUE ): Q1 GAAP EPS of -$0.48 misses by $0.12 . More news on: Cue Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the firs...
CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation f...
Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class ...
Unorthodox screeners for unorthodox times One of my favorite screeners on EquitiesLab.com is called after the names of three famous traders, the legendary one (Wyckoff) and two contemporary ones (O'Neill and Minervini). I created it on the basis of my readings of their books and my own in...
- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic HNSCC patients to be amended to include combination of CUE-101 with standard of care KEYTRUDA as first-line therapy - Preliminary data from early patient cohorts ...
Cronos to Restate 2019 Financial Statements, Board Member Leaves Cronos Group ( CRON ) announced that it will be restating certain items for the first three quarters of FY 2019. It also stated that quarterly reports belonging to those periods ‘should no longer be relied upon....
Cue Biopharma, Inc. (CUE) Q4 2019 Earnings Conference Call March 17, 2020, 04:30 PM ET Company Participants Ashley Robinson - IR Dan Passeri - President and CEO Anish Suri - Chief Scientific Officer Ken Pienta - Chief Medical Officer Kerri-Ann Millar - VP of Finance and Princ...
Cue Biopharma (NASDAQ: CUE ): Q4 GAAP EPS of -$0.37 in-line. More news on: Cue Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...